Evaluation of the safety and immune protection of OMPAC, PAPF, and EBPSs recombinant subunit vaccines Developed for Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae in mice
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114151 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Zhenyu Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Science and Technology, Shihezi University 832000 Shihezi City, Xinjiang, China. Hauptthemen laut MEDLINE: Streptococcus agalactiae, Escherichia coli, Staphylococcus aureus, Streptococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Shihezi University.
Abstract (Originalsprache)
Bacterial mastitis in dairy cow is often caused by a combination of bacterial infections, such as Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae. Currently, there is no effective vaccine against the disease. Therefore, we constructed a recombinant subunit vaccine by fusing gene fragments of E. coli OMPA and OMPC, S. aureus EBPS, and S. agalactiae PGK, AP1, AP2, and FBSA. These gene fragments were combined into three fusion proteins: OMPAC, EBPSs, and PAPF. Mice were immunized with the three fusion proteins either alone or in combination. The test results showed that immunization with OMPAC, EBPSs, and PAPF individually or in combination could induce high titers of antibodies in the mice. Additionally, 21 days post-immunization, IFN-γ levels were significantly increased in all groups of mice, suggesting that immunization with OMPAC, EBPSs, and PAPF, whether alone or in combination, was effective in inducing antibody production. This indicates that OMPAC, EBPSs, and PAPF were effective in inducing both humoral and cellular immunity in mice. Furthermore, immunization with OMPAC, EBPSs, and PAPF individually or in combination were effective in protecting mice from E. coli, S. aureus, and S. agalactiae infections. Importantly, a mixture of the three fusion proteins was relatively safe for pregnant female mice. In conclusion, we successfully constructed and expressed recombinant subunit vaccines of OMPAC, EBPSs and PAPF and verified that these vaccines rapidly induced high levels of specific antibodies while reducing bacterial loads in the organs of mice. This lays the theoretical foundation and data support for the development of novel subunit vaccines against mastitis in dairy cows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Animal Science and Technology, Shihezi University 832000 Shihezi City, Xinjiang, China.
- Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China.
- Xinjiang Center for Animal Disease Control and Prevention, Urumqi, China.
- College of Animal Science and Technology, Shihezi University 832000 Shihezi City, Xinjiang, China. Electronic address: 724050645@qq.com.
- College of Animal Science and Technology, Shihezi University 832000 Shihezi City, Xinjiang, China. Electronic address: chuangfu_chen@163.com.
Förderung
- Shihezi University
Zitieren
APA
Xu, Z., Zhang, Y., Wang, Y., Wu, A., Meng, C., Li, W., Yi, J., & Chen, C. (2025). Evaluation of the safety and immune protection of OMPAC, PAPF, and EBPSs recombinant subunit vaccines Developed for Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114151
Vancouver
Xu Z, Zhang Y, Wang Y, Wu A, Meng C, Li W, et al. Evaluation of the safety and immune protection of OMPAC, PAPF, and EBPSs recombinant subunit vaccines Developed for Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114151
BibTeX
@article{Xu2025,
author = {Xu, Zhenyu and Zhang, Yuchen and Wang, Yueli and Wu, Aodi and Meng, Chuang and Li, Wei and Yi, Jihai and Chen, Chuangfu},
title = {Evaluation of the safety and immune protection of OMPAC, PAPF, and EBPSs recombinant subunit vaccines Developed for Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae in mice},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114151}
}
EUVIMED